In the EV+pembrolizumab combination, if a patient achieves an excellent response but develops prohibitive EV-related toxicities like neuropathy, a viable strategy is to discontinue EV and maintain the patient on pembrolizumab monotherapy. This can sustain the response while improving quality of life.

The impact of GLP-1 medications like Ozempic extends far beyond weight loss. Emerging research shows profoundly positive second-order effects, including halving metastatic cancer growth rates and potentially delaying dementia and Alzheimer's, signaling a massive, unexpected public health revolution.

While known for weight loss, GLP-1 agonists are also highly effective for managing hyperglycemia from both steroids and PI3K inhibitors. Using low or "micro" doses can be very helpful in cancer patients, providing glucose control while minimizing GI side effects like nausea.

For patients with life-threatening metastatic urothelial cancer and poorly controlled diabetes, experts advise starting enfortumab vedotin (EV) without delay. The immediate cancer threat outweighs the risks of a high hemoglobin A1C. Aggressive glucose monitoring and early endocrinologist involvement are initiated simultaneously to manage the hyperglycemia.

The neuropathy caused by polatuzumab vedotin can be severe and is not always reversible. Clinicians must be vigilant in assessing for symptoms like numbness or difficulty with fine motor skills and be prepared to reduce the dose promptly to prevent long-term, debilitating side effects.

Beyond weight management, preliminary evidence suggests GLP-1 agonists may help with vasomotor symptoms (hot flashes) and arthralgia (joint pain). The proposed mechanism is indirect, likely through reduced inflammation from fat loss and less mechanical load on joints, representing a novel potential benefit for patients.

While severe (Grade 3+) neuropathy from enfortumab vedotin is rare, oncologists emphasize that Grade 2 toxicity is common and significantly impairs patients' quality of life. This 'moderate' side effect is often painful and interferes with daily activities, warranting an immediate hold on treatment, not just waiting for Grade 3.

To prevent irreversible toxicities like neuropathy from enfortumab vedotin, clinicians should proactively set expectations. Emphasize that dose adjustments are normal and part of a long-term strategy. Framing it as a "marathon, not a sprint" encourages patients to report side effects early, rather than hiding them for fear of stopping treatment.

The mechanism of GLP-1s extends far beyond fat reduction. By increasing insulin sensitivity in every cell—liver, kidney, nerve cells—they effectively help cells process insulin like they did when younger. This positions them as a pervasive longevity product, similar to statins, for pushing back on age-related decline.